Soumya Swaminathan, Chief Scientist at WHO said that WHO’s goal is to have a broad portfolio of vaccines approved for emergency use and to expand access to populations everywhere.
New Delhi: The World Health Organisation’s (WHO) technical advisory group is likely to meet on Tuesday as a decision is awaited on the Emergency Use Listing (EUL) of Bharat Biotech’s COVID-19 vaccine – Covaxin.
The WHO is likely to consider granting EUL for Covaxin in today’s meeting.
Earlier, the agency’s Chief Scientist Soumya Swaminathan had stated that the WHO’s goal is to have a broad portfolio of vaccines approved for emergency use and to expand access to populations everywhere.
“The technical advisory group will meet on Oct 26th to consider EUL for #Covaxin. @WHO has been working closely with @BharatBiotech to complete the dossier,” Swaminathan said in a recent tweet.
The WHO had on Friday said that the approval process sometimes takes a longer time.
“The process of thoroughly evaluating a vaccine for use and recommending it sometimes takes a long time but it has to be ensured that the right advice is given to the world “even if it takes another week or two,” it had said.
The WHO has, till now, approved COVID-19 vaccines manufactured by Pfizer-BioNTech, US pharma majors Johnson & Johnson, Moderna, China’s Sinopharm and Oxford-AstraZeneca for emergency use.
According to Bharat Biotech, Phase III clinical trials of Covaxin had demonstrated an efficacy rate of 77.8 per cent.
Bharat Biotech’s Covaxin is one of the three COVID-19 vaccines being used in India for the massive nationwide inoculation drive. The other two are the Serum Institute of India’s Covishield and Russia’s Sputnik V.